Anticoagulation: What GPs need to know

British National Formulary (BNF) (2024) Warfarin sodium. Available at: https://bnf.nice.org.uk/drug/warfarin-sodium.html (accessed 15 June 2025).

Connolly SJ Ezekowitz MD Yusuf S , et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 361(12): 1139–1151. DOI: 10.1056/NEJMoa0905561.

Connolly SJ Milling TJ Jr. Eikelboom JW , et al. (2019) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine 380(14): 1326–1335. DOI: 10.1056/NEJMoa1814051.

Eikelboom JW Connolly SJ Brueckmann M , et al. (2013) Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine 369(13): 1206–1214. DOI: 10.1056/NEJMoa1300615.

European Heart Rhythm Association (EHRA) (2021) The 2021 EHRA Practical Guide on the use of NOACs in patients with atrial fibrillation. European Heart Journal 42(37): 373–498. DOI: 10.1093/eurheartj/ehab648.

European Society of Cardiology (ESC) (2024) 2024 ESC Guidelines for the management of atrial fibrillation. Available at: www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation# (accessed 6 January 2026).

European Society of Cardiology (ESC) & European Association for Cardio-Thoracic Surgery (EACTS) (2025) 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. Available at: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf194/8234488 (accessed 6 January 2026).

Hart RG Pearce LA Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 146(12): 857–867. DOI: 10.7326/0003-4819-146-12-200706190-00007.

Hindricks G Potpara T Dagres N , et al. (2020) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.

Jones NR Round T (2021) Venous thromboembolism management and the new NICE guidance: what the busy GP needs to know. British Journal of General Practice 71(709): 379. DOI: 10.3399/bjgp21X716765.

Kearon C Akl EA Ornelas J , et al. (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2): 315–352. DOI: 10.1016/j.chest.2015.11.026.

Keeling D Baglin T Tait C , et al. (2011) Guidelines on oral anticoagulation with warfarin – Fourth edition. British Journal of Haematology 154(3): 311–324. DOI: 10.1111/j.1365-2141.2011.08753.x.

Konstantinides SV Meyer G Becattini C , et al. (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal 41(4): 543–603. Available at: https://academic.oup.com/eurheartj/article/41/4/543/5556136.

Kotalczyk A Gue YX Potpara TS , et al. (2021) Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom: are changes on the horizon? Expert Opinion on Pharmacotherapy 22(8): 1061–1070. DOI: 10.1080/14656566.2021.1879050.

Lane DA Potpara TS Lip GYH (2024) Sex as a risk factor in atrial fibrillation: time to simplify stroke risk assessment. The Lancet Regional Health – Europe 40: 100967. DOI: 10.1016/j.lanepe.2024.100967.

Medicines and Healthcare products Regulatory Agency (MHRA) (2020) Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic. Drug Safety Update 14(10): 5. Available at: www.gov.uk/drug-safety-update/warfarin-and-other-anticoagulants-monitoring-of-patients-during-the-covid-19-pandemic (accessed 6 January 2026).

NHS Derbyshire Medicines Management (2024) Oral anticoagulation prescribing guidelines. Derbyshire ICS. Available at: https://derbyshiremedicinesmanagement.nhs.uk/assets/Clinical_Guidelines/Formulary_by_BNF_chapter_prescribing_guidelines/BNF_chapter_2/Oral_anticoagulation.pdf (accessed 22 June 2025).

NHS England (2021) National Patient Safety Alert – Inappropriate anticoagulation of patients with a mechanical heart valve. Available at: www.england.nhs.uk/publication/national-patient-safety-alert-inappropriate-anticoagulation-of-patients-with-a-mechanical-heart-valve (accessed 6 January 2026).

NHS Nottingham Nottinghamshire ICB (2025) Warfarin prescribing information sheet for primary care prescribers. Nottingham: Nottinghamshire Area Prescribing Committee. Available at: www.nottsapc.nhs.uk/media/rgshhhd4/warfarin-prescribing-information-sheet.pdf (accessed 20 June 2025).

NICE (2019) Stroke and transient ischaemic attack in over 16s: Diagnosis and initial management [NG128]. Available at: www.nice.org.uk/guidance/ng128 (accessed 10 June 2025).

NICE (2020) Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158. Available at: www.nice.org.uk/guidance/ng158/chapter/Recommendations#anticoagulation-treatment-for-suspected-or-confirmed-dvt-or-pe (accessed 6 January 2026).

NICE (2021a). Atrial fibrillation: diagnosis and management [NG196]. Available at: www.nice.org.uk/guidance/ng196 (accessed 8 June 2025).

NICE (2021b). Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban [TA697]. Available at: www.nice.org.uk/guidance/ta697 (accessed 8 June 2025).

Otto CM Nishimura RA Bonow RO , et al. (2020) 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Journal of the American College of Cardiology 77(4): e25–e197. DOI: 10.1016/j.jacc.2020.11.018.

Pollack CV Jr. Reilly PA Eikelboom JW , et al. (2015) Idarucizumab for dabigatran reversal. New England Journal of Medicine 373(6): 511–520. DOI: 10.1056/NEJMoa1502000.

PrescQIPP CIC (2022) 282: Anticoagulation in venous thromboembolism (VTE) 2.0. PrescQIPP. Available at: https://prescqipp.info/media/6195/282-anticoagulation-part-2-venous-thromboembolism-vte-20.pdf (accessed 15 June 2025).

Sterne JA Bodalia PN Bryden PA , et al. (2017) Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment 21(9): 1–386. DOI: 10.3310/hta21090.